Generic Name and Formulations:
Sodium hyaluronate 0.84%; per 2mL; soln for intra-articular inj.
Treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics (eg, acetaminophen).
Remove synovial fluid or effusion before inj. Give as a single intra-articular inj. >21yrs: 2mL in one knee only once weekly for 3 weeks.
≤21yrs: not established.
Knee joint infections. Skin diseases or infections in area of the inj site.
Do not inject by intravascular route. Severe intra-articular effusion. Lymphatic or venous stasis in leg. Advise patients to avoid strenuous or prolonged weight-bearing activities for approx. 48hrs following inj. Pregnancy, nursing mothers: not established.
Avoid use of disinfectants containing quaternary ammonium salts; hyaluronan can precipitate in their presence. Concomitant other intra-articular inj: not studied.
Inj site pain, arthralgia, joint effusion/warmth/stiffness/swelling, arthritis, gait disturbance, arthropathy.
Single-use pre-filled syringe—1 (w. needle)
Join MIMS Learning now to manage all your CPD and notes in one place!
Already a MIMS Learning member?Sign In Now »
This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...
This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...
Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...
In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...
This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...
Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...